WETS
VRTX icon

Wealth Enhancement Trust Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152K Sell
306
-2
-0.6% -$886 0.02% 317
2026
Q1 		$138K Sell
308
-52
-14% -$24.2K 0.02% 313
2025
Q4 		$163K Buy
+360
New +$155K 0.02% 280

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Wealth Enhancement Trust Services's VRTX Position: Q2 2026 in Review

Wealth Enhancement Trust Services reduced its Vertex Pharmaceuticals (VRTX) stake by 0.65% in Q2 2026, selling an estimated $886 and leaving 306 shares worth $152K. The position accounts for 0.02% of the portfolio, ranked #317.

Wealth Enhancement Trust Services first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $163K in Q4 2025. 1,322 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Wealth Enhancement Trust Services held 306 shares of Vertex Pharmaceuticals worth $152K as of Q2 2026.
  • Wealth Enhancement Trust Services sold 2 Vertex Pharmaceuticals shares in Q2 2026, an estimated $886.
  • Vertex Pharmaceuticals made up 0.02% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #317 holding.
  • Wealth Enhancement Trust Services first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Wealth Enhancement Trust Services's Vertex Pharmaceuticals position peaked at $163K in Q4 2025.
  • 1,322 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.